Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study-Reference-Cited by-同舟云学术

Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study

Published:2019-05 Issue: Volume:151 Page:65-73
ISSN:0168-8227
Container-title:Diabetes Research and Clinical Practice
language:en
Short-container-title:Diabetes Research and Clinical Practice

Author:

Ku Eu Jeong^ORCID,Lee Dong-Hwa,Jeon Hyun Jeong,Oh Tae Keun

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference24 articles.

1. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus;Defronzo;Diabetes,2009

2. Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive Type 2 diabetes management algorithm – 2018 executive summary;Garber;Endocr Pract,2018

3. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD);Davies;Dia Care,2018

4. Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: a network and cumulative meta-analysis of randomized controlled trials;Tang;Diabetes Obes Metab,2017

5. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis;Zaccardi;Diabetes Obes Metab,2016

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and cerebrovascular diseases: a meta-analysis of controlled clinical trials;Frontiers in Endocrinology;2024-08-23

2. Mechanism and use strategy of uric acid-lowering drugs on coronary heart disease;IJC Heart & Vasculature;2024-08

3. The Efficacy and Safety of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors in Real-World Clinical Practice: Potential Cautionary Use in Elderly Patients with Type 2 Diabetes (T2D);Diabetes Therapy;2024-05-21

4. Comparative Outcomes of Empagliflozin to Dapagliflozin in Patients With Heart Failure;JAMA Network Open;2024-05-02

5. A Comparison of Efficacy among Syrian diabetic patients treated with Empagliflozin versus Dapagliflozin, a Randomized, Triple-blind, Two-period crossover study;Research Journal of Pharmacy and Technology;2023-10-31